#1 Clinical Trials Search in Europe

Marstacimab

Marstacimab is an innovative drug currently being studied in clinical trials for the treatment of hemophilia, a rare bleeding disorder. This article explores the ongoing research on Marstacimab, its potential benefits for patients with hemophilia A and B, and the various aspects of the clinical trials being conducted to evaluate its safety and effectiveness.

Table of Contents

What is Marstacimab?

Marstacimab, also known by its research name PF-06741086, is a new medication being developed to treat hemophilia[1][2][3]. It’s an innovative drug that works differently from traditional hemophilia treatments. Instead of replacing the missing clotting factors, marstacimab targets a protein in the body that helps regulate blood clotting.

What Conditions Does Marstacimab Treat?

Marstacimab is being studied for the treatment of:

  • Severe Hemophilia A: This is a rare bleeding disorder where the blood doesn’t clot normally due to a lack of clotting factor VIII. People with severe hemophilia A can bleed excessively, even from minor injuries[1].
  • Moderately Severe to Severe Hemophilia B: Similar to Hemophilia A, but caused by a deficiency in clotting factor IX[3].

Importantly, marstacimab is being studied for use in patients both with and without inhibitors. Inhibitors are antibodies that the immune system develops against replacement clotting factors, making traditional treatments less effective[1].

How is Marstacimab Administered?

Marstacimab is given as a subcutaneous injection, which means it’s injected under the skin. The current studies are testing weekly injections of the medication[1][3]. This could be more convenient for patients compared to some current treatments that require more frequent injections.

Two delivery devices are being tested:

  • Prefilled Pen (PFP): A device that contains a pre-measured dose of the medication.
  • Prefilled Syringe (PFS): A syringe that’s already filled with the correct dose of the medication[2].

These devices could make it easier for patients to administer the medication at home.

Current Clinical Trials

Several clinical trials are currently underway to study marstacimab:

  1. Switching from Emicizumab to Marstacimab: This study is looking at how safe and effective it is for patients with severe Hemophilia A to switch from a medication called emicizumab to marstacimab[1].
  2. Comparing Delivery Devices: This study is comparing the prefilled pen and prefilled syringe to see if they deliver the medication equally well[2].
  3. Pediatric Study: This trial is studying marstacimab in children and adolescents (ages 1-17) with severe Hemophilia A or moderately severe to severe Hemophilia B[3].

Safety and Side Effects

As with any new medication, researchers are carefully monitoring the safety of marstacimab. Some of the potential side effects being watched for include:

  • Injection site reactions (such as redness or swelling where the medication is injected)
  • Allergic reactions
  • Development of antibodies against the medication
  • Thrombotic events (formation of blood clots)
  • Changes in laboratory test results[3]

It’s important to note that not all patients will experience these side effects, and the ongoing clinical trials will help determine how common and severe these side effects might be.

Future Prospects

If the clinical trials show positive results, marstacimab could offer several benefits for people with hemophilia:

  • Less frequent dosing (weekly injections)
  • Potential for at-home administration
  • Effectiveness in patients with and without inhibitors
  • Possible use in both Hemophilia A and B

However, it’s important to remember that marstacimab is still in the testing phase. More research is needed to fully understand its effectiveness and safety profile before it can be approved for general use[1][2][3].

Aspect Details
Drug Name Marstacimab (also known as PF-06741086)
Target Conditions Severe Hemophilia A, Moderately severe to severe Hemophilia B (with or without inhibitors)
Administration Weekly subcutaneous injection (150 mg or 300 mg)
Age Groups Studied Adolescents and adults (12 to 75 years), Pediatric patients (1 to 17 years)
Primary Outcomes Safety, Annualized Bleeding Rate (ABR), Pharmacokinetics, Pharmacodynamics
Secondary Outcomes Quality of life, Joint health, Incidence of different types of bleeds
Trial Durations Ranging from 6 to 14 months (including screening, treatment, and follow-up)
Key Features Potential alternative to current prophylactic treatments, Being studied as a switch from emicizumab in some trials

FAQ

  • What is Marstacimab? Marstacimab is a new drug being studied for the treatment of hemophilia A and B. It is administered as a weekly subcutaneous injection and is designed to help prevent bleeding episodes in patients with this rare blood clotting disorder.
  • Who can participate in Marstacimab clinical trials? The clinical trials for Marstacimab include various groups. Some studies focus on adolescents and adults (12 to 75 years old) with severe hemophilia A, while others include pediatric patients (1 to 17 years old) with severe hemophilia A or moderately severe to severe hemophilia B, with or without inhibitors.
  • How is Marstacimab administered in the trials? In the clinical trials, Marstacimab is typically administered as a weekly subcutaneous (under the skin) injection. The dose may vary depending on the specific trial, but common doses include 150 mg or 300 mg once weekly.
  • What are the main goals of the Marstacimab clinical trials? The primary goals of the Marstacimab trials are to assess its safety, how the body processes the drug (pharmacokinetics), and how effective it is in preventing bleeding episodes. Researchers also aim to evaluate its impact on patients' quality of life and compare it to standard treatments.
  • How long do the Marstacimab clinical trials last? The duration of Marstacimab clinical trials varies. Some studies last approximately 6 months, while others may extend up to 14 months, including screening, treatment, and follow-up periods. The treatment period typically ranges from 4 to 12 months.

Ongoing Clinical Trials on Marstacimab

  • Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Croatia Czechia Denmark France Germany +3

  • Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Czechia Denmark France Germany Italy +2

Glossary

  • Hemophilia A: A genetic bleeding disorder caused by a deficiency in blood clotting factor VIII, leading to impaired blood clotting and increased risk of bleeding.
  • Hemophilia B: A genetic bleeding disorder caused by a deficiency in blood clotting factor IX, also resulting in impaired blood clotting and increased bleeding risk.
  • Inhibitors: Antibodies that the immune system develops against infused clotting factors, making them less effective in treating bleeding episodes in hemophilia patients.
  • Prophylaxis: A preventive treatment approach where medication is given regularly to prevent bleeding episodes before they occur.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Annualized Bleeding Rate (ABR): A measure used to assess the effectiveness of hemophilia treatments by calculating the number of bleeding events a patient experiences over a year.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and therapeutic effects.
  • Anti-Drug Antibody (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which may affect its efficacy or safety.
  • Neutralizing Antibody (NAb): Antibodies that can reduce or eliminate the effectiveness of a drug by binding to it and preventing it from working properly.

References

  1. https://clinicaltrials.gov/study/NCT06703606
  2. https://clinicaltrials.gov/study/NCT04832139
  3. https://clinicaltrials.eu/trial/study-on-marstacimab-for-children-with-severe-hemophilia-a-or-b-with-or-without-inhibitors/